Candel Therapeutics (NASDAQ:CADL – Get Free Report) and Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Insider and Institutional Ownership
13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 16.6% of Candel Therapeutics shares are held by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Candel Therapeutics and Oncolytics Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Candel Therapeutics | N/A | -41.00% | -26.81% |
| Oncolytics Biotech | N/A | -438.11% | -143.90% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Candel Therapeutics | 0 | 1 | 3 | 1 | 3.00 |
| Oncolytics Biotech | 0 | 1 | 4 | 0 | 2.80 |
Candel Therapeutics presently has a consensus price target of $20.00, indicating a potential upside of 292.16%. Oncolytics Biotech has a consensus price target of $5.00, indicating a potential upside of 257.14%. Given Candel Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Candel Therapeutics is more favorable than Oncolytics Biotech.
Risk and Volatility
Candel Therapeutics has a beta of -0.9, suggesting that its stock price is 190% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
Earnings & Valuation
This table compares Candel Therapeutics and Oncolytics Biotech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Candel Therapeutics | $120,000.00 | 2,333.25 | -$55.18 million | ($0.69) | -7.39 |
| Oncolytics Biotech | N/A | N/A | -$23.14 million | ($0.27) | -5.19 |
Oncolytics Biotech has lower revenue, but higher earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Candel Therapeutics beats Oncolytics Biotech on 8 of the 13 factors compared between the two stocks.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
About Oncolytics Biotech
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
